Modality
Degrader
MOA
Anti-Aβ
Target
USP1
Pathway
Cell Cycle
Huntington'sParkinson's
Development Pipeline
Preclinical
~Jul 2019
→ ~Oct 2020
Phase 1
Jan 2021
→ May 2027
Phase 1Current
NCT07361569
2,701 pts·Huntington's
2021-01→2027-05·Completed
2,701 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-05-231.1y awayPh2 Data· Huntington's
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1/2
Complet…
Catalysts
Ph2 Data
2027-05-23 · 1.1y away
Huntington's
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07361569 | Phase 1/2 | Huntington's | Completed | 2701 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| RLA-6817 | Relay Therapeutics | Phase 3 | TIGIT | |
| Lisoosocimab | Zealand Pharma | Approved | KIF18A | |
| PRA-419 | Praxis Precision | Approved | Cl18.2 | |
| TNG-8610 | Tango Ther | NDA/BLA | GIP-R | |
| Tezesotorasib | Enliven | Phase 2 | USP1 |